Effects of Uric Acid on the NO Production of HUVECs and its Restoration by Urate Lowering Agents

Abstract

Background: Although urate impaired the endothelial function, its underlying mechanism remains unknown. We hypothesized that urate impaired nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs) via activation of uric acid transporters (UATs).

Purpose and method: In the present study, we studied effects of urate on NO production and eNOS protein expression in HUVEC cells in the presence and absence of urate lowering agents using molecular biological and biochemical assays.

Results: HUVECs expressed the 4 kinds of UATs, URATv1, ABCG2, MRP4 and MCT9. Exposure to urate at 7 mg/dl for 24 h significantly reduced production of NO. Pretreatment with benzbromarone, losartan or irbesartan normalized NO production. The same exposure resulted in dephosphorylation of endothelial NO synthase (eNOS) in HUVECs. Again pretreatment with benzbromarone, losartan or irbesartan abolished this effect.

Conclusion: Urate reduced NO production by impaired phosphorylation of eNOS in HUVEC via activation of UATs, which could be normalized by urate lowering agents.

Key words

urate - no production - eNOS - HUVEC

• References

• 1 Feig DI, Kang DHJR. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
• 2 Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410
• 3 Bonora E, Targher G, Zenere MB et al. Relationship of uric acid concentration to cardiovascular risk factors in young men: role of obesity and central fat distribution (The Verona Youn Men Atherosclerosis Risk Factors Study). Int J Obes Relat Metab Disord 1996; 20: 975-980
• 4 Misawa T, Takahama M, Kozaki T et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 2013; 14: 454-460
• 5 Hediger Ma, Johnson RJ, Miyazaki H et al. Molecular physiology of urate transport. Physiology (Bethesda) 2005; 20: 125-133
• 6 Wright AF, Rudan I, Hastie ND et al. A “complexity” of urate transporters. Kidney Int 2010; 78: 446-452
• 7 Price KL, Sautin YY, Long DA et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006; 17: 1791-1795
• 8 Zhang Y, Yamamoto T, Hisatome I et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol 2013; 375: 89-96
• 9 Sugihara S, Hisatome I, Kuwabara M et al. Depletion of uric acid due to SLC22A12 (URAT1) loss-of-function mutation causes endothelial dysfunction in hypouricemia. Circ J 2015; 79: 1125-1132
• 10 Kang DH, Han L, Ouyang X et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005; 25: 425-433
• 11 Sautin YY, Nakagawa T, Zharikov S et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584-C596
• 12 Chao H, Liu J, Lin J et al. Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin 2008; 29: 1301-1312
• 13 Corry DB, Eslami P, Yamamoto K et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26: 269-275
• 14 Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562
• 15 Maruhashi T, Nakashima A, Soga J et al. Hyperuricemia is independently associated with endothelial dysfunction in postmenopausal women but not in premenopausal women. BMJ Open 2013; 3: e003659
• 16 Park JH, Jin YM, Hwang S et al. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development. Nitric Oxide 2013; 32: 36-42
• 17 Khosla 1 UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742
• 18 Hediger Ma, Johnson RJ, Miyazaki H et al. Molecular physiology of urate transport. Physiology (Bethesda) 2005; 20: 125-133
• 19 Wright AF, Rudan I, Hastie ND et al. A “complexity” of urate transporters. Kidney Int 2010; 78: 446-452
• 20 Anzai N, Ichida K, Jutabha P et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283: 26834-26838
• 21 Nakamura M, Anzai N, Jutabha P et al. Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. J Pharmacol Sci 2010; 114: 115-118
• 22 Nakanishi T, Ohya K, Shimada S et al. Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate. Nephrol Dial Transplant 2013; 28: 603-611
• 23 Kuwabara M, Niwa K, Nishi Y et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res 2014; 37: 785-789
• 24 Iwanaga T, Sato M, Maeda T et al. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211-217
• 25 Ishizaka N, Ishizaka Y, Toda E et al. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005; 25: 1038-1044
• 26 Goldberg MR, Bradstreet TE, McWilliams EJ et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25: 37-46
• 27 Sica DA, Marino MR, Hammett JL et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997; 62: 610-618
• 28 Maharani N, Ting YK, Cheng J et al. Molecular mechanisms underlying urate-induced enhancement of Kv1.5 channel expression in HL-1 atrial myocytes. Circ J 2015; Oct 16. [Epub ahead of print]